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Inhibition of nuclear factor-kappa B
enhances the tumor growth of ovarian
cancer cell line derived from a low-grade
papillary serous carcinoma in p53independent pathway
Xue Xiao1,5†, Gong Yang3,4,5†, Peng Bai2, Shunping Gui1, Tri M. Bui Nyuyen7, Imelda Mercado-Uribe5, Mei Yang1,
Juan Zou6, Qintong Li1, Jianguo Xiao5, Bin Chang8, Guangzhi Liu5, He Wang1*† and Jinsong Liu5*†

Abstract
Background: NF-kB can function as an oncogene or tumor suppressor depending on cancer types. The role of NF-kB
in low-grade serous ovarian cancer, however, has never been tested. We sought to elucidate the function of NF-kB in
the low-grade serous ovarian cancer.
Methods: The ovarian cancer cell line, HOC-7, derived from a low-grade papillary serous carcinoma. Introduction of a
dominant negative mutant, IkBαM, which resulted in decrease of NF-kB function in ovarian cancer cell lines. The
transcription ability, tumorigenesis, cell proliferation and apoptosis were observed in derivative cell lines in comparison
with parental cells.
Results: Western blot analysis indicated increased expression of the anti-apoptotic proteins Bcl-xL and reduced
expression of the pro-apoptotic proteins Bax, Bad, and Bid in HOC-7/IĸBαM cell. Further investigations validate this
conclusion in KRAS wildtype cell line SKOV3. Interesting, NF-kB can exert its pro-apoptotic effect by activating mitogenactivated protein kinase (MAPK) phosphorylation in SKOV3 ovarian cancer cell, whereas opposite changes detected in
p-MEK in HOC-7 ovarian cancer cell, the same as some chemoresistant ovarian cancer cell lines. In vivo animal assay
performed on BALB/athymic mice showed that injection of HOC-7 induced subcutaneous tumor growth, which was
completely regressed within 7 weeks. In comparison, HOC-7/IĸBαM cells caused sustained tumor growth and
abrogated tumor regression, suggesting that knock-down of NF-kB by IĸBαM promoted sustained tumor growth and
delayed tumor regression in HOC-7 cells.
Conclusion: Our results demonstrated that NF-kB may function as a tumor suppressor by facilitating regression of low
grade ovarian serous carcinoma through activating pro-apoptotic pathways.
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* Correspondence: wanghe_cd@126.com; 19811454@qq.com; 15908149408@
163.com
†
Equal contributors
1
Department of Gynecology and Obstetrics, West China Second University
Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
5
Department of Pathology, University of Texas M. D. Anderson Cancer
Center, Houston, TX, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Xiao et al. BMC Cancer (2016) 16:582

Background
NF-kB has long been recognized as a potent tumor promoter and a lot drugs are targeting NF-kB in cancer treatment. However, more recent evidence suggests that NFkB can also inhibit the tumor growth. The first pieces of
evidence that NF-kB can function as a tumor suppressor
came from studies of chemically-induced skin cancer, in
which inhibition of NF-kB via IĸB-SR expression in
keratinocytes enhanced the multiplicity of squamous
cell carcinomas in response to 7,12-Dimethylbenz(a)anthracene (DMBA). Furthermore, inhibition of
NF-kB in primary human keratinocytes promoted
Ras-mediated transformation. The tumor suppressing
activity of NF-kB was explained either by inhibition of
cell cycle or by downregulating of MAPKs pathway [1–3].
Members from distinct signaling cascades of the MAPK
family such as SAPK/JNK, p38 MAPK, and ERK1/2 are
known to determine cell fate during DNA damage, mitogenic stimuli, and survival. Nevertheless, in different cell
line and under different irritation, the involved signaling
cascades of MAPKs are different [1, 4–7]. In particular,
the interplay between NF-kB and JNK may play a critical
role in the development of Den- induced hepatocellular
carcinoma (HCC), while ERK activation was seen in RasIĸBα tumors and patient’s squamous cell carcinoma
(SCCs).
Our previous study showed that in ovarian carcinoma cell
lines OVCA433 and OVCR3, introduction of a dominant
negative mutant IĸBα (IĸBαM), which constitutively suppresses NF-kB function, resulted in cell proliferation and
inhibition of apoptosis through ERK/MAPKs pathway. Despite the solid evidence supporting the potential relevance of
both activation of Ras/MAPK pathway and blockade of
NF-kB in at least a subset of spontaneous human epidermal
SCCs, the exact functions latent mechanism of NF-kB and
MAPK pathways in low grade ovarian cancer are still unknown. The KRAS and BRAF are the upstream of MAPKs
pathway and genetic alterations in these genes are associated with carcinogenesis [8–11]. Because therapeutics interventions inhibiting Ras and NF-kB pathways are being
developed to treat human ovarian cancer, it is crucial to assess the effects of altering these regulators. Since the quantities of active Ras-GTP were comparable in Ras-IĸBα
tumors and in human epithelial cancer cells with defined
Ras mutations [12, 13], it is not hard to propose that the
tumorigenesis was not due to expression of more active
Ras than is expressed by endogenous mutant alleles. The
mechanism about Ras and its phophorylated MAPK targets
and the activity of NF-kB were uncertain, however, by critical shortage of ras mutation cell line and mouse model.
Excitedly, HOC-7 provides us a kras mutation model to
learn about the potential mechanism of these factors.
The origin, development and outcome of low-grade
ovarian cancer are different from high-grade ovarian
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cancer. P53 overexpression and mutations are infrequent
in low-grade ovarian cancer but occur in as many as 50
to 80 % of high-grade ovarian cancer. Depending on the
morphologic, immunohistochemical and molecular genetic analyses of p53 comparing with low- and high-grade
ovarian cancer, functional mutations, defined as mutations leading to the alteration of the structure of
encoded protein, were detected in 50.8 % of high-grade
cancer and 8.3 % of low-grade cancer. In our study, the
role of p53 in NF-kB-related tumor suppression was also
mentioned.
In this study, we investigated the functional role of
NF-kB in cancer development using ovarian cancer
as a model system. Our study provides first experimental evidence that NF-kB may inhibit the HOC-7
tumorigenesis in a p53 independent signaling
manner.

Methods
Cell lines, media and plasmids

HOC-7 with an average doubling time of 16.4 days is a
kind gift from Dr R. N. Buick (University of Arizona,
Tucson), which was derived from ascites of a patient
with a well-differentiated Stage III serous adenocarcinoma of the ovary [9, 14]. SKOV3 human ovarian cancer
cell lines were bought from the American Type Culture
Collection (Rockville, MD). HOC-7 and SKOV3 cell
lines were cultured in Minimum Essential Alpha 1×/
RPMI-1640 medium (GIBCO BRL, Life Technologies,
Gaithersburg, MD) supplemented with 10 % fetal bovine
serum (HyClone, Logan, UT) at 37 °C with 5 % CO2.
Both HOC-7 and SKOV3 were transfected with dominant
negative mutant IĸB, henceforth IĸBαM, using N-[1-(2,3dioleoyloxyl)propyl]-N,N,N-trimethylammoniummethyl
sulfate liposomal transfection reagent (Boehringer
Mannheim, Indianapolis, IN) and selected by neomycin antibiotics (2.5ug/ml) for 14 days. The plasmid
used for stable transfection was a pBabe-U6/puromycin
vector (5.4 kb) containing IkBαM under cytomegalovirus (CMV) promoter expression control. The
primers used to sequence IkBαM were p1: catat
ggatccatgtttcagccagctgggcacg p2: cctatctcgagttataatg
tcagacgctggcctc. The mutation place in the serines
32 and 36 of IkBα were replaced by glycine and
alanine, which damaged the phosphorylation and
followed proteolysis, eventually led to the irreversible
binding to Rel/NF-kB and inhibited its translocation
in nuclei [9, 15–18]. In addition, we transfected
HOC-7 and IkBαM expressing HOC-7 cell line with
p53 siRNA, the positive colony were selected by
puromycin (300ug/ml). SiRNAs against p65 and p53
and control siRNA were purchased from Santa Cruz
Biotechonology.
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Mutantional analysis of KRAS in HOC-7 and SKOV3
cell lines

Genomic DNA was purified from all of the HOC-7 and
SKOV3 cell lines using the QIAGEN’s DNeasy Tissue
Kit (QIAGEN Inc, Chatsworth, CA, USA). PCR was
performed ensued by nucleotide sequencing using the
iCycler (Bio-Rad, Hercules, CA, USA), which is including the exon 1 of KRAS. The primers used to sequence
were: 5-taaggcctgctgaaaatgactg-3 (forward); 5-tggtcctg
caccagtaatatgc-3 (reverse); and 5-ctgcaccagtaatatgcata
ttaaaac-3 (sequencing); The thermal profile was: first
denaturation step 95 °C 2 min, followed by 95 °C
30 s, 58 °C for 30s, 72 °C for 35 s, total 35 cycles;
72 °C for 10 min [19, 20]. The Lasergene program
(DNASTAR, Madison, WI) was used to analyze these
sequences.
Electrophoretic mobility shift assay (EMSA) and luciferase
reporter assay

The electrophoretic mobility shift assay was performed
as described before. Briefly, the nuclear extracts of different cell lines were prepared by lysed in nuclear extract
buffer (20 mM HEPES, 400 mM NaCl, 1 Mm EDTA,
1 Mm EGTA, 10 μM dithiothreitol, 20 μg/ml leupeptin,
20 μg/ml aprotinin, 500 μg/ml benzamidine) and the
concentrations were determined using the Coomassie
brilliant blue G250 assay kit. Double-stranded deoxyoligonucleotides containing the NF-kB consensus recognition site (5′-AGT TGA GGG GAC TTT CCC AGG
C-3′ and 5′-GCC TGG GAA AGT CCC CTC AAC
T-3′, Santa Cruz Biotechnology Inc, Santa Cruz, CA)
were labeled with (r-32p)ATP using T4 polynucleotide
kinase according to the protocol. The nuclear probe
was incubated with the radiolabeled probe DNA
(3.5pmol, 10 μCi) and 4 μl 5 × binding buffer. For the
supershift, the proteins were incubated with p65 or
p50 monoclonal antibody before 32p labeled. All of the
DNA-protein complexes were resolved on 5 % PAGE in
Tris/glycine buffer after incubated at room temperature
for 30 min. For the NF-kB transcription assay, seeded cells
were precultured to 75 % confluence and transfected with
and HIV promoter-driven luciferase cDNA plasmid, and
then tested according to promega kit.
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Soft agar colony formation assay

Soft agar growth assay was performed as previously described (Difco, Detroit, MI). The four cell lines were
mixed with 0.4 % agar were overlaid above the supporting 0.6 % agar and cultured total 25 days with replenished medium. Random fields were recorded using a
Leica TCS4D confocal scanning laser microscope (Leica,
Solms, Germany) and the total number and the size of
the colonies were counted.
Western blot analysis

Western blot analysis was performed as preciously described. Lysates of treated cells or tumor samples were
collected and lysed in radioimmunoprecipitation assay
buffer. Equal amounts of proteins were resolved on
SDS-PAGE and then transferred onto a polyvinylidene
difluoride membrane. Specific primary antibodies were
used for the following molecules : IĸBα(Cabiochem, San
Diego, CA, USA), p65, Iĸĸα, Iĸĸβ, AKT, p-AKT, MEK,
p-MEK, ERK, p-ERK, p38, caspase-10, caspase-1, cyclinA,
cyclinB, PUMA, BID, CIAP, Bad, p-Bad, PKC (Cell signaling Technology), JNK2/1, p-JNK, TSP1, Bcl-2, Bcl-xL,
Bax, APAF1, Fas, caspase-8, Mrg1, cyclinD, p53, MMP1
(Santa Cruze Biotechnology, CA), caspase-9, caspase-3
(BioLegend). β-Actin (Santa Cruze Biotechnology, CA)
was used to assess the equal loading. The phosphorylated
protein controls obtained from blots that had been
stripped and re-probed for the same sample lane. Sixty
microgram of cell protein extract was loaded per lane. CS710 Calibrated Imaging Densitometer (Bio-Rad) was
utilized for densitometric quantification.
Apoptosis detection

Derivative cells and control cells were cultured to 80 %
confluence. Cells were harvested after being washed
three times with ice-cold phosphate-buffered saline
(PBS). Subsequently, cells were labeled with Annexin V
and propidium iodide according to the manufacturer’s
protocol (BD ApoAlert Annexin V-FITC Apoptosis kit;
BD Biosciences, PaloAlto, CA) [21]. The percentage of
apoptotic cells was determined by (M2) peak in the
histogram generated by FACSCalibur system and Cell
Quest software (BD Biosciences).

Cell proliferation assay

Tumor xenograft in nude mice

Cell proliferation was determined by examined by 3-[4,
5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide
assay (MTTassay; Sigma) with the CellTiler 96 Aqucous
One Solution Cell Proliferation Assay Kit (Promega) according to the manufacturer’s protocol. Four different cell
lines HOC-7, HOC-7 IĸBαM, HOC-7 P53i and HOC-7
IĸBαM P53i were seeded at 5 × 103 cells/well in 96-well
tissue culture plates. Cell growth curve was assessed every
24 h and totally 3 days.

The xenograft tumor model has been described earlier [22].
Briefly, 5 × 106 cells of either wild type HOC-7, SKOV3,
IĸBαM expressing HOC-7 and SKOV3 or P53-inactivating
cells were subcutaneously injected into 4- to 6-weekold female BALB/athymic nude mice (NCI-Frederick,
NIH). Each group includes 8 mice. One week after
implantation, the mice were checked every 2 days per
week. The control group received saline (PBS) only.
The same quantity of saline was used in these groups
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to resuspend different cell lines. General clinical observation of the mice included determination of syndrome, side effect and body weight. To determine
tumor size, we measured two perpendicular diameters
of the xenograft in centimeters by calibers. Tumor
weight was then estimated using formula 1/2a × b2,
where a is the long diameter and b is the short diameter [23, 24]. 66 days after the first injection, all mice
were euthanized by carbon dioxide asphyxiation and
the tumor tissues were processed for immunohistochemistry staining followed by 10 % formalin fixation
overnight. All protocols for animal use were reviewed
and approved by the Animal Care Committee of West
China Second University hosipital in accordance with Institutional Animal Care and Use Committee guidelines.
Patient tissue specimens

The use of tissue blocks and chart reviews were approved
by the Institutional Review Board of Sichuan University.
The specimens, including controls, used in our study were
preserved and stored by the Tissue Bank Core Facility at
Sichuan University. Detailed quality control procedures
for tissue sampling were chosen and implemented by the
Tissue Bank Core Facility at Sichuan University. Patients
had been treated with either chemotherapy or irradiation
by the treating physicians, and the selection of patient tissues was not based on the treatments. Follow up information was updated through March 2011 by reviewing
medical records. The randomly selected formalin-fixed
paraffin-embedded tissues included normal ovarian tissues
(n = 20) and low-grade serous ovarian carcinomas (n =
416) were not matched. Tumor sample collection and tissue microarray construction have been described previously [25, 26]. Briefly, ovarian tissue microarray blocks
were diagnosed in duplicate by two gynecologic pathologists who reviewed hematoxylin and eosin–stained
sections and constructed by taking core samples from
morphologically representative areas of paraffinembedded tumor tissues and assembling them on a recipient paraffin block. The follow-up protocol have been mentioned previously, the same as the characteristics of
exclusion criteria and eligible participants. All of the participants provided written informed consent and the study
protocol was agreed by the institutional review boards of
Sichuan University (no.11789).
Immunohistochemical staining and analysis

The streptavidin-peroxidase immunohistostaining method
for NF-kB p65 was performed as described elsewhere
[27, 28]. Briefly, samples were fixed in 10 % formalin
buffer and embedded in paraffin. Tissue sections
(4 μm thick) were steamed in universal decloaker
(Biocare Medical, Walnut Creek, CA, USA) for antigen retrieval, followed by 19 min protein-blocking (Biocare
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Medical). All slides were first incubated against NF-kB
p65 (1:500, for 1 h at room temperature; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) and then
treated with secondary antibody (Biocare Medical)
and horseradish peroxidase for 15 min each. The tissues were stained for 3 min with high sensitivity 3,3′diaminobenzidine tetrahydrochloride, counterstained with
hematoxylin, dehydrated and then mounted [29, 30].
Statistical analysis

Statistical analysis was performed by using Fisher’s exact
test at different time points for the mean tumor sizes of
each group. X-tile software was used to find the optimal
cut-off point. Monte Carlo simulations was used to determine the prognostic significance. Disease-specific survival
rates were calculated by the Kaplan-Meier method and
compared by the log-rank test. Cox proportional hazards
regression models in Statistica software (SAS Institute,
SAS Language Reference, version 8, SAS Institute,
Inc) were used for multivariate analyses of survival.
The rest of statistical analysis was performed by using
Student’s t-test (STATISTICA6 software, StatSoft,
Tulsa, OK). Differences with P-value was less than
0.05 were considered significant. All statistical tests
were two-sided.

Results
KRAS mutation exists in HOC-7 ovarian cancer cell lines
and human low grade serous ovarian cancers

Ovarian cancer cell lines HOC-7 and transformed cells
were first analysed for mutations in the KRAS gene. As
shown in Fig. 1a, KRAS exon 1 mutation (from ACA to
AGC) were initially screened by PCR-SSCP and then confirmed by direct sequencing. Xenograft tumors produced
by subcutaneous injection of HOC-7, HOC-7 IĸBαM cell
lines were evaluated by histopathology. Slides showed
similar morphology as low-grade human serous ovarian
carcinoma. Following immunohistochemical staining
showed that HOC-7 and HOC-7 IĸBαM tumor tissues expressing KRAS strongly due to persistent activity of
KRAS/MAPKs pathway, which confirm the KRAS mutation (Fig. 1b).
Inhibition of constitutive activation of NF-kB in HOC-7
carrying IĸBα

To study the importance of NF-kB pathway in tumorigenesis, we selectively blocked NF-kB activation by
targeted expression of a super-repressor form of IĸBα.
In EMSA assessment of nuclear extracts from both
transfected and parental HOC-7 cells, IĸBα-transfected
cells showed reduced DNA binding and gene transcription activity of NF-kB compared with parental
cells (Fig. 1c-d). Western blot showed overexpression
of IkBα and decreased expression of Ikkα and p65 in
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Fig. 1 Genetic specific of ovarian cancer cells. a Sequence of KRAS gene in HOC-7 and relative transgenic cells. b The expression of kras, braf, p21
and p53 in HOC-7 and relative transgenic tumor tissues by immunohistochemical staining (400×). c Electrophoretic mobility shift assays showing
that the binding of NF-kB to its promoter DNA consensus sequence was reduced in IkBαM-transfected cells. d Luciferase-reporter assays showing
the reduced transcriptional activity of NF-kB. Error bars =95 % confidence intervals. Blank represents the empty control vector, wild type represents the
luciferase reporter vector, which has an HIV promoter containing binding sites to NF-kB protein. The intensity of luciferase activity thus represents the
cellular NF-kB activity. Mutant represents the luciferase reporter vector with NF-kB binding sites eliminated. Ectopic expression of IkBαM markedly
reduced the reporter activity, indicative of dampened cellular NF-kB activity

nuclei of HOC-7 IĸBαM cells. As shown in Fig. 4a,
clear bands were shown in expected 37 kDa size,
which represent endogenous IĸBα. Interesting, an
extra band was appeared at a little bit higher size
(40 kDa) in IĸBαM transfected HOC-7 cells, but not
in parental HOC-7 cells. To further test the inhibiting
function of IkBαM in NF-kB mediated gene expression, downstream markers of NF-kB were measured
using western blotting. As expected, IkBαM repressed
expression of PUMA logged in NF-kB downstream
pathway, indicating that IkBαM was stably expressed
in HOC-7 cells and inhibited the constitutive function
of NF-kB, as shown in Fig. 4b.

Consitutive activation of NF-kB inhibits tumor growth in
ovarian cancer cell lines

To compare the cell growth rate between parental cells
with constitutive NF-kB activation and transgenic cells
with stably expression of IĸBαM, we tested its effect on
tumor growth in two ovarian cancer cell lines, SKOV3
and HOC-7. As shown in Fig. 2a, HOC-7 carrying
IkBαM resulted in 48 % cell growth increase compared
with parental cells. Additionally, prolonged culture of
cells vastly increased this growth differences. Furthermore, HOC-7 cells carrying IkBαM showed 2.4 times increase anchorage independent growth on soft agar
compared with parental cells, which exhibit dramatic
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Fig. 2 NF-kB induced tumor growth in HOC-7 cells. a HOC-7-IkBαM cells displayed dramatically increase of cell proliferation compare with parental
cells. b colony formation of HOC-7 transgenic cells and parental cells. c In vivo, NF-kB induced tumor growth both in SKOV3 and HOC-7 xenograft
nude mice“ to ”Fig. 2. NF-kB induced tumor growth in HOC-7 cells. a HOC-7-IkBαM cells displayed dramatically increase of cell proliferation compare
with parental cells. b In vivo, NF-kB induced tumor growth both in SKOV3 and HOC-7 xenograft nude mice (c) BCL-xl is the key protein involved in the
phenotypic shift. d colony formation of HOC-7 transgenic cells and parental cells. e Data represent the mean ± standard error of the mean (SEM) percentage
of the number of invasion cells compared to the control; *p < 0.05, n = 3. Error bars = 95 % confidence intervals. f NF-kB - induced apoptosis correlated
with MAPKs pathway and apoptosis pathway in vivo. The western blot data from the mice tumors showed that expression of p-MEK increased in mice
tissue carrying HOC-7 IkBαM compare with those carrying HOC-7 vector, while the expression of p-ERK instead of p-MEK decreased in mice tissue
carrying SKOV3 IkBαM compare with those carrying SKOV3 vector. Generally, NF-kB induced apoptosis in a MAPKs dependent pathway in vivo

colony-forming capacity (Fig. 2d-e). These data indicated
that block of NF-kB activity by IkBαM could effectively
induce growth and migration ability in ovarian epithelial
cells.
NF-kB inhibits the tumor growth in BALB/athymic nude
mice

To investigate if inhibition NF-kB activity can induce
tumor growth in vivo, we first established a xenograft
model of HOC-7 IkBαM and SKOV3 IkBαM cells in

BALB/athymic nude mice using parental cells as control.
All of the mice given i.p. injection developed tumor
showed for lethargy, poor appetite and abdominal enlargement. Injection of HOC-7 into subcutis of nude
mice led to tumor growth up to one week followed by
complete regression at the end of 66 days. In contrast,
subcutaneous injection of HOC-7 expressing IĸBαM resulted in tumor growth for up to five weeks followed by
a steeply increase for 4 weeks (from 38 days to 66 days).
At the 38 days of experiments, the subcutaneous tumor
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growth in 8 mice inoculated with HOC-7-IkBαM increased 82 % tumor weight as compared with that in
HOC-7 control mice. 87 % increase of s.c tumor volume
in HOC-7-IkBαM was observed (Fig. 2b). Similarly, nude
mice injection with IĸBαM-transfected SKOV3 had
more subcutaneous tumor growth than those injected
with parental cells. The expression of IĸBαM promotes
tumor growth and abrogates tumor regression. Interesting, the western blot data of IkBαM expression of mice
tumors in Fig. 2f indicated that IkBαM expression correlate with MAPKs pathway and apoptosis pathway,
which coincided with the data in vitro (Fig. 2f ).
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Constitutive activation of NF-kB induced cell death and
apoptosis

To further evaluate the mechanisms involved in the
transformation of ovarian epithelial cells mediated by
IkBαM, we examined apoptosis in HOC-7 IkBαM and
its parental cells, as detected by Annexin V staining, and
in xenograft mouse tissures, as measured by an ApoBrdU-labeled in situ DNA fragmentation assay (Fig. 3ac). The incidence of apoptotic reduced 86 % in HOC-7
IkBαM cells compared with its respective parental cells.
These data indicate that block of NF-kB reduced the
levels of cellular apoptosis in HOC-7 cells. Western blot

Fig. 3 Tumor apoptosis following introduction of IkBαM in ovarian cancer cell lines. a Apopotic cells measured by Annexin V staining of cells with
or without IkBαM expression. Error bars = 95 % confidence intervals. b Percentatge of apoptotic cells measured by flow cytometry. c representative images
of xenograft tumor tissue showing apoptosis, which is indicated by DNA breaks (green) detected by an Apo-BrdU (green) in situ DNA fragmentation assay
(×400, TUNEL). PI, red
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analysis cellular apoptosis pathways and indicated upregulation of anti-apoptotic proteins including Bcl-xL,
the reduction of pro-apoptotic proteins Bax, Bad, and
Bid, and sequentially, reduction the activation of caspases 3, 8, 9 and 10 (Fig. 4b-d). The level of the antiapoptotic protein Bcl-xL was increased in SKOV3/
IkBαM cells compare with parental cells. Interesting, no
changes in the level of Bcl-2 were visualized in SKOV3/
IkBαM cells, whereas the Bcl-2 dramatically decreased
in HOC-7 cells transfected with IkBαM (Fig. 4c-d). We
reasonable doubt BCL-xl is the key protein involved in
the phenotypic shift. Data showed that HOC-7 IkBαM
cells over expressed BCL-xl compared with parental
cells. The downstream factors such as caspase-3 and
caspase-9 showed decrease expression. On the contrary,
HOC-7 IkBαM cells carrying BCL-xl siRNA indicated
increased expression of downstream factors, such as
casapse-3 and casapse-9 (Fig. 2c). The results demonstrated that the NF-kB-mediated tumor suppression may
be related to Bcl-xL, and this crucial marker change is
keep consistent in the five independent ovarian cancer
cell lines (SKOV3, HOC-7, HEY, OVCA433 and
OVCR3) although they may have different genetic backgrounds [31].

NF-kB - induced apoptosis correlated with MAPKs
pathway

To study the role of Ras and MAPKs in human ovarian
tumorigenesis, we compared the expression of signaling
molecules involved in the mitogen-activted protein kinase (MAPK) pathway between KRAS mutant cell line
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HOC-7 and the KRAS wild type cell line SKOV3. Cells
expressing IkBαM showed marked hyperplasia in either
HOC-7 or SKOV3 transgenic cells, indicating that the
blockage of NF-kB induce tumor proliferation independent on the mutational status of RAS/RAF. In nude mice,
both of transgenic cell lines showed tumor inducing
function. All together, In contrast with the result presented by others that Ras and NF-kB in a setting more
relevant to human tumorigenesis, NF-kB inhibit the
tumor growth in a Ras-independent way. Interestingly,
western blotting showed high expression of p-MEK in
the HOC-7 IkBαM cells, no changes were seen in
MAPKs downstream pathway, including the JNK, ERK
and p38 sub pathways (Fig. 4a). On the contrary, according to our previous data published, in SKOV3-IkBαM
cell, dephosphorylation of ERK was observed as the upstream of mitochondria apoptosis pathway, suggesting
that NF-kB induced apoptosis is associated with phosphorylation of mitogen-activated protein kinases in
KRAS wild type cell line SKOV3 but not in KRAS mutation cell line HOC-7 which expression persistent activity
of KRAS-MAPKs pathway [31].
Nuclear localization of NF-kB is associated with favorable
prognoses for ovarian cancer patients

Although NF-kB was reported to be a poor prognostic
indicator in ovarian cancer, our study suggested that
NF-kB may function as a tumor suppressor in low-grade
ovarian cancer. Therefore, we further analyzed whether
nuclear NF-kB p65 expression predicts prognosis in patients with low-grade ovarian serous carcinoma by
immunostaining a tissue microarray consisting of 416

Fig. 4 NF-kB - induced apoptosis in MAPKs independent pathway. a Cell apoptosis pathway are associated with inhibition of NF-kB activity. Detection
of MAP kinases proteins in HOC-7 ovarian cancer cells with or without IkBαM by western blotting. b Detection of apoptosis-associated proteins in
HOC-7 ovarian cancer cells with or without IkBαM. c-d NF-kB and p53 pathway related proteins in HOC-7 and relative transgenic cells by western
blotting. β- actin was used as a loading control
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low-grade ovarian cancer cases. We found that the nuclear expression of p65 was low (<12 %, nuclear positive
tissues) in 38.9 % of cases (162/416) but high (≥12 %,
nuclear positive tissues) in 61.1 % of cases (254/416).
We found a significant statistical correlation between
cases with low and high expression of nuclear p65 and
their prognostic (P < 0.01). Patients with high nuclear expression of p65 had longer overall survival than did patients with low p65 expression (Fig. 5d). The 5-year
survival time was 21 months longer in cases with high
NF-kB p65 nuclear expression than in cases with low
NF-kB p65 nuclear expression. Furthermore, the cumulative proportions of patients surviving 24, 60, and
120 months were greater among patients with high nuclear p65 expression than patients with low nuclear p65
expression (0.755, 0.427,0.081 vs 0.623, 0.164, 0.038).
Images representing patient tumor tissues with high and
low nuclear expression of p65 are shown in Fig. 5a.
These results suggest that NF-kB nuclear activation is
associated with outcome of disease in patients with ovarian cancer.

Page 9 of 13

Crucial pathways that involved in low-grade papillary
serous ovarian carcinoma growth due to inhibition of
nuclear factor-kappa B

The heatmap displays all genes that were differentially
expressed between these cells (Fig. 5c), in which red or
green colors indicate up-or down regulated genes, respectively. The NF-kB1, NF-kB2 and MAPK15 genes expression were obviously decreased in ovarian cancer cell
lines with dominant negative IkBαM. Furthermore, comparing SKOV3 with SKOV3 IkBαM, apoptosis relative
genes such as PUMA were decreased and proliferation
relative gene CIAP and MDM2 were increased. Similar,
comparing HOC-7 with HOC-7 IkBαM draw the same
conclusion. Different with SKOV3 cell line, HOC-7
shows different change in MAPKs pathway factors including MAPK15, KRAS and BRAF. These results verified that NF-kB - induced apoptosis in MAPKs
independent pathway. Furthermore, the expression of
Bcl-2 is different between SKOV3 IkBαM and HOC-7
IkBαM cells [31]. As shown in Fig. 4d, even though
mitochondrial pathway is the shared downstream of

Fig. 5 Correlation of nuclear localization of p65 NF-kB and clinicopathologic characteristics and a model of the NF-kB role in ovarian cancer. a
Representative images showing high and low nuclear expression of p65 in high-grade ovarian cancer tissues. b A model illustrating that NF-kB
suppresses tumorigenesis by inhibiting anti-apoptosis through the regulation of MAPK phosphorylation and apoptosis pathway. c Detection of
NF-kB1, NF-kB2, MAPK15, KRAS, BRAF, PUMA, MDM2, CIAP by heatmap. d Kaplan-Meier curves showing favorable overall survival rates in patients
with low-grade serous ovarian cancer are associated with nuclear expression of p65
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both SKOV3 and HOC-7, the data indicated that NF-kB
reduced Bcl-2 expression and lead to apoptosis in
SKOV3 cells depending on dramatically increased the
levels of phosphorylated MEK1/2 and ERK1/2, whereas
in HOC-7 cells, NF-kB directly affects downstream
apoptosis pathway through CIAP and caspase-3 and get
the same results eventually (Fig. 5b).
NF-kB - induced apoptosis in p53 independent pathway

In an attempt to elucidate the crosstalk between NF-kB
and p53, we generated retrovirus expressing small interfering RNA (siRNA) against p53 in HOC-7 and HOC-7IkBαM cell lines. Western blotting showed p53 expression was decreased after infection with p53i RNA. As
described previously, we examined the cell proliferation,
anchorage independent growth on soft agar of these cell
lines carrying knock out p53, knock out NF-kB, double
knock out NF-kB and p53, or parental cell. As shown in
Fig. 2a-d, both HOC-7-IkBαM and HOC-7-IkBαM-p53i
cells displayed dramatically increase of cell proliferation
and colony formation as compared with parental cells.
Surprisingly, we found that treatment of HOC-7 IkBαM
cells with small interfering RNA against p53 reversed
the decrease of pro-apoptotic protein Bcl-2, wheras no
big changes in the level of anther apoptotic-related
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proteins Bcl-xL, caspase 8. caspase 9 and caspase 10.
These results demonstrated that blocking NF-kB function in ovarian cancer cells may promote the proliferation by increasing the levels of cellular anti-apoptisis
proteins Bcl-xL in p53 independent way. In order to verify above point of view in vivo, we first established xenograft models with HOC-7 IkBαM and HOC-7 IkBαM
p53i cells using parental cells as control. As shown in
Fig. 6a-b, nude mice injection with HOC-7 IĸBαM p53i
had more subcutaneous tumor growth than those
injected with HOC-7 IĸBαM cells. Similarly, nude mice
carry HOC-7 p53i had more subcutaneous tumor
growth than those injected with HOC-7 cells. All the
changes are subtle. Decreasing expression of p53 gene
will not affect the tumor development induced by
IkBαM (Fig. 6c).

Discussion
For a long time, the role of NF-kB was described as
oncogeic with respect to its function in promoting cell
proliferation, angiogenesis, transformation and invasion
[9, 32–34]. A novel role for NF-kB has been suggested
in several recent studies, specifically, involvement of NFkB in tumor suppress has been demonstrated in skin
and liver [35–37]. It seems NF-kB can either promote or

Fig. 6 NF-kB induced apoptosis in p53-independent pathway in BALB/athymic nude mice. a Inhibition of NF-kB activity can induce tumor growth in
p53-independent pathway in vivo. b Tumor growth following etopic expression of IkBαM in BALB/athymic nude mice in p53-independent pathway. c
A model illustrating that inhibition of NF-kB signaling in ovarian tissue results in an increased proliferation rate and the development of ovarian tumors.
Furthermore, neither mutations in the KRAS nor decreasing expression of p53 gene can affect the tumor development induced by IkBαM
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inhibit carcinogenesis depending on the tumor type or cell
specialty. Because therapeutics inhibiting NF-kB pathway
are being used as a strategy in cancer treatment, it is crucial to explore potential mechanism and altering function
of NF-kB that can protect or contribute to apoptosis. In
this study, we characterized an ovarian cell line derived
from a well-differentiated (low grade) serous carcinoma
and defined a tumor suppressor role of NF-kB in tumor
development. We demonstrated that introduction of a
dominant negative mutant IĸBα (IĸBαM), which can firmly
binding with NF-kB and inhibit NF-kB translocation, resulted in cell proliferation and inhibition of apoptosis in
low grade ovarian epithelial cancer in vitro and in vivo.
Ras, the important genes in tumorigenesis, were found
to contain activating point mutations in human low
grade ovarian epithelial carcinoma cell line HOC-7 [8].
The mutations of KRAS may initiate the development of
additional genetic “hit” in tumorigenesis [38, 39]. Since
the mutations of KRAS are early events involved in
tumor initiation, HOC-7 provide a good model to explore the connection between ras-raf-MAPKs pathway
and NF-kB in tumorgenesis [6]. HOC-7 cell lines have
the KRAS mutation, presumably keeping activated the
MAPKs pathway, showed phosphorylation of MEK after
infection of IkBαM, while SKOV3 cell line, which sequenced to be the KRAS wild type, showed dephosphorylation of both MEK and ERK following the infection of
IkBαM. No matter MAPK pathway activated or not,
both transgenic cell line SKOV3- IkBαM and HOC-7IkBαM showed potential tumorigenesis potent both in
vitro and in vivo. All together, the IkBαM construct in
cancer cell can induce the tumor growth in a ras independent way. NF-kB can serve as a tumor suppressor
through its pro-apoptotic function in ovarian cancer
cells in Ras-MAPKs independent pathway.
Accumulating evidence shows that nuclear function of
IkBα is its participation with NF-kB in an autoregulatory
negative feedback loop culminating in the translocation
of NF-kB into the nucleus. The recent identification
showed that phosphorylation of CBP by Ikkα can switch
the binding reference of CBP from p53 to NF-kB, which
provided an important link between p53 and NF-kB
[40–42]. Furthermore, Ikkα up-regulates the expression
of p53 antagonist MDM2, which can dominantly localized in the nucleus and promotes increased degradation
of p53 [41–43]. Since Ikkα was regarded to release upon
phosphorylation IkBα, it was therefore postulated that
IkBα maybe affect the balance between p53 and NF-kB.
In our study, the HOC-7 p53i showed overexpression of
Ikkα, implied the increase activity of NF-kB [44, 45]. In
parallel with these results, we also found that HOC-7
IkBα decreased the expression of NF-kB responsive promoter CIAP and increased those with p53-responsive
promoter (p21 and mdm2). All of above suggested that
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Ikkα and downstream IkBα regulated the antagonism
crosstalk between NF-kB and p53. To further examine if
p53 paly a possible role in the development of transgenic
tumors, we set up the xenograft model of HOC-7-53i,
HOC-7-IkBαM and HOC-7-IkBαM-p53i. We observed
an increased tumor growth in HOC-7 p53i, suggestion
an involvement of p53 in the development of these tumors, which consist with previous knowledg.e that the
tumor suppressor p53 inhibits cell growth through activation of cell-cycle arrest and apoptosis. Mutation analysis of exons 5–8 of p53 in HOC-7 parental and
transfected cells did not reveal any mutation. Kevin M
showed that induction of p53 causes an activation of
NF-kB which correlates with the function of p53 to induce apoptosis [46]. Inhibition of NF-kB activity abrogated p53-induced apoptosis, indicating that NF-kB is
essential in p53-mediated cell apoptosis. Loss of NF-kB
activity specifically abrogated the p53-mediated apoptosis response. Activation of NF-kB by p53 was different
from that mediated by tumour-necrosis factor-a and involved MEK1 and the activation of pp90rsk. Inhibition
of MEK1 blocked activation of NF-kB by p53 and completely abrogated p53-induced cell death. Our studies
showed knocking down p53 augment tumor growth in
HOC-7 IkBαM cells, suggesting that NF-kB is crucial
but not cover all part in p53-mediated cell apoptosis.

Conclusions
The results indicated a new role of NF-kB in the inhibition of tumor growth. Inhibition of NF-kB signaling in
ovarian tissue results in an increased proliferation rate
and the development of ovarian tumors. Furthermore,
neither mutations in the KRAS nor decreasing expression of p53 gene can affect the tumor development induced by IkBαM [47]. The drugs used targeted the NFkB, where p53 is itself an important mediator of chemosensitivity, such therapy seems very dangerous to the
tumor treatment due to its repression of p53-mediated
tumor cell death function. Liu demenstrated that NF-kB
can be reprogrammed to a tumor-promoting oncogene
conferring drug resistance following standard chemotherapy with carboplatin and paclitaxel, clinical treatment of ovarian cancer using anti-NF-kB agents should
be cautiously considered and guided by specific markers
that can distinguish whether NF-kB is functioning as a
tumor suppressor or an oncogene. Comparing Bcl-xL
expression between primary and recurrent ovarian tumors after chemotherapy might be a useful marker to
determine the function of NF-kB and direct clinic individualized drug therapy.
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